VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer

Condition:   Squamous Cell Carcinoma of the Head and Neck
Interventions:   Biological: VX15/2503;   Biological: Ipilimumab;   Biological: Nivolumab
Sponsors:   Emory University;   Vaccinex Inc.
Not yet recruiting

https://ift.tt/2P3Fb4X